<DOC>
	<DOCNO>NCT00394745</DOCNO>
	<brief_summary>The purpose study evaluate potential effect valsartan lipid subfractions parameter lipid metabolism patient essential hypertension metabolic syndrome .</brief_summary>
	<brief_title>Effect Valsartan Lipid Subfractions Hypertensive Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male female outpatient &gt; = 18 year age Visit 1 Hypertension ( systolic blood pressure &gt; = 140 mmHg &lt; 170 mmHg and/or diastolic blood pressure &gt; = 90 mmHg &lt; 105 mmHg Elevated triglycerides Metabolic syndrome define Adult Treatment Panel III criterion MSSBP &gt; = 170 mmHg and/or MSDBP &gt; = 105 mmHg time Visit 1 Visit 2 Diabetes mellitus Patients treat lipid lower drug last 6 week prior Visit 1 A history cardiovascular disease , include angina pectoris , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , transient ischemic attack , stroke , peripheral artery disease , heart failure NYHA II IV Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertension , Metabolic Syndrome , lipid subfractions</keyword>
</DOC>